ScaleReady is at the forefront of advancing cell and gene therapy (CGT) through its innovative G-Rex Grant Program, a collaborative initiative aimed at enhancing the manufacturing processes for CGT. The company emphasizes the importance of maintaining high cell quality throughout the research and clinical phases, utilizing G-Rex bioreactors that prevent cell phenotype drift during scale-up. This technology, combined with high-quality reagents, ensures that cell phenotype profiles remain consistent, facilitating a seamless transition from small-scale research to large-scale clinical applications. ScaleReady's commitment to quality is further demonstrated through its partnerships, which provide access to GMP (Good Manufacturing Practice) raw materials and customizable workflows that adapt to various manufacturing needs.

In addition to its bioreactor technology, ScaleReady offers a range of GMP-grade cytokines sourced from Bio-Techne, which are crucial for immune cell therapy manufacturing. These cytokines, including IL-2, IL-7, IL-15, and IL-21, are produced in an animal-free environment, ensuring high bioactivity and low variability, which are essential for successful T and NK cell therapies. The company prioritizes rigorous quality control and regulatory compliance, ensuring that both research-grade and GMP products maintain the same high standards. This focus on quality and customization allows ScaleReady to support clients in scaling their cell therapy processes efficiently while minimizing risks associated with raw material supply and performance.

United States

ScaleReady is a consulting company that specializes in providing strategic planning and organizational development services to help businesses scale and achieve growth.

ScaleReady

Company Details